Marc R. Arnone - Concepedia

Author

Marc R. Arnone

GlaxoSmithKline (United States)

Also Known As

Marc Arnone, Marc R. Arnone

Publications

913

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)Research Triangle Park Foundation Bristol-Myers Squibb (United States)

About

Marc R. Arnone is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	859
2	Cell Biology	4	4	637
3	Natural Sciences	3	3	311
4	Biochemistry	3	3	311
5	Chemical Biology	1	1	100

Marc R. Arnone

Publications

913

Citations

H-Index

Page 1

	Year	Citations
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors Tara Rheault, John Stellwagen, George M. Adjabeng, ACS Medicinal Chemistry Letters B-raf-driven TumorsAntitumor ActivityHyperactive SignalingTumor BiologyMedicinal Chemistry	2013	253
Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions Alastair J. King, Marc R. Arnone, Maureen R. Bleam, PLoS ONE DermatologyTumor BiologySignaling PathwayReceptor Tyrosine KinasePreclinical Characterization	2013	212
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues Lata T. Gooljarsingh, Christine Fernandes, Kang Yan, Proceedings of the National Academy of Sciences Biochemical RationaleDrug TargetDrug ResistanceMedicinal ChemistryHsp90 Inhibitor Geldanamycin	2006	118
Synthesis and Biological Evaluation of 1-Aryl-4,5-dihydro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-one Inhibitors of Cyclin-Dependent Kinases Jay A. Markwalder, Marc R. Arnone, Pamela A. Benfield, Journal of Medicinal Chemistry High-throughput Screening StrategyDrug TargetMolecular BiologyChemical BiologyPharmaceutical Chemistry	2004	100
Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay Ronald D. Snyder, Marc R. Arnone Mutation research. Fundamental and molecular mechanisms of mutagenesis ChromatinBiochemistryFunctional InteractionsTopoisomerase IiNatural Sciences	2002	93
Identification of Peptide Substrates for Human MMP-11 (Stromelysin-3) Using Phage Display Weijun Pan, Marc R. Arnone, Marvin Kendall, Journal of Biological Chemistry	2003	54
Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation Sylvie Laquerre, Marc R. Arnone, Katherine G. Moss, Molecular Cancer Therapeutics Tumor RegressionB-rafv600e MutationCell DeathSelectivity Towards B-rafCancer Biology	2009	54
Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup John Stellwagen, George M. Adjabeng, Marc R. Arnone, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryPotent B-rafv600e InhibitorsMedicineRational Drug DesignDrug Development	2011	29

Page 1